CCM
TSBX

CAAS Capital Management’s Turnstone Biologics TSBX Stock Holding History

CAAS Capital Management’s Portfolio TSBX Stock Details TSBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-45,831
Closed -$117K – 649
2023
Q4 		$117K Sell
45,831
-30,677
-40% -$80.1K 0.01% 405
2023
Q3 		$301K Buy
+76,508
New +$682K 0.02% 455

Other funds holding TSBX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
7IH
72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

CAAS Capital Management's TSBX Position: Q1 2024 in Review

CAAS Capital Management sold out of Turnstone Biologics (TSBX) in Q1 2024, closing a stake of 45,831 shares — an estimated $117K sold.

CAAS Capital Management first reported a position in TSBX in Q3 2023 and held it in 2 quarters. The position peaked at $301K in Q3 2023. 40 funds tracked by Wall St. Rank hold TSBX as of Q1 2024.

  • CAAS Capital Management reported no remaining Turnstone Biologics position as of Q1 2024 after selling out during the quarter.
  • CAAS Capital Management sold 45,831 Turnstone Biologics shares in Q1 2024, an estimated $117K.
  • CAAS Capital Management first reported a position in Turnstone Biologics in Q3 2023 and held it in 2 quarters.
  • CAAS Capital Management's Turnstone Biologics position peaked at $301K in Q3 2023.
  • 40 funds tracked by Wall St. Rank held Turnstone Biologics as of Q1 2024.

Based on CAAS Capital Management's 13F filing for Q1 2024, filed 26 Apr 2024.